This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Randomized controlled trial of memantine in dementia associated with Parkinson’s disease


Leroi, Iracema, Overshott, Ross, Byrne, E. Jane, Daniel, Emily, Burns, Alistair


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 24, No.: 8, Pages.: 1217-1221

Year of Publication



The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson’s disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD.; (c) 2009 Movement Disorder Society.

Bibtex Citation

@article{Leroi_2009, doi = {10.1002/mds.22495}, url = {}, year = 2009, month = {jun}, publisher = {Wiley-Blackwell}, volume = {24}, number = {8}, pages = {1217--1221}, author = {Iracema Leroi and Ross Overshott and E. Jane Byrne and Emily Daniel and Alistair Burns}, title = {Randomized controlled trial of memantine in dementia associated with Parkinson{textquotesingle}s disease}, journal = {Movement Disorders} }


adverse, aged, aged, 80 and over, complications, dementia, double-blind method, drug evaluation, drug therapy, events, excitatory amino acid antagonists, female, humans, male, memantine, mental status schedule, parkinson disease, severity of illness index, therapeutic use, time factors, treatment outcome

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime